title: Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications.
abstract: OBJECTIVE
  To investigate the potential mechanisms through which conventional antipsychotic medication (APM) might act, the specific causes of death in elderly patients newly started on conventional APM were compared with those of patients taking atypical APM.
  
  
  METHODS
  Cohort study.
  
  
  METHODS
  Community.
  
  
  METHODS
  All British Columbia residents aged 65 and older who initiated a conventional or atypical APM between 1996 and 2004.
  
  
  METHODS
  Cox proportional hazards models were used to compare risks of developing a specific cause of death within 180 days of APM initiation. Potential confounders were adjusted for using traditional multivariable, propensity-score, and instrumental-variable adjustments.
  
  
  RESULTS
  The study cohort included 12,882 initiators of conventional APM and 24,359 initiators of atypical APM. Of 3,821 total deaths within the first 180 day of use, cardiovascular (CV) deaths accounted for 49% of deaths. Initiators of conventional APM had a significantly higher adjusted risk of all CV death (hazard ratio (HR)=1.23, 95% confidence interval (CI)=1.10-1.36) and out-of-hospital CV death (HR=1.36, 95% CI=1.19-1.56) than initiators of atypical APM. Initiators of conventional APM also had a higher risk of death due to respiratory diseases, nervous system diseases, and other causes.
  
  
  CONCLUSIONS
  These data suggest that greater risk of CV deaths might explain approximately half of the excess mortality in initiators of conventional APM. The risk of death due to respiratory causes was also significantly higher in conventional APM use.
authors.affiliation: Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA. ssetoguchi@partners.org
authors.forename: Soko
authors.initials: S
authors.lastname: Setoguchi
authors.forename: Philip S
authors.initials: PS
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Alan Brookhart
authors.forename: Claire F
authors.initials: CF
authors.lastname: Canning
authors.forename: Liljana
authors.initials: L
authors.lastname: Kaci
authors.forename: Sebastian
authors.initials: S
authors.lastname: Schneeweiss
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000401:mortality; D014150:Antipsychotic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001955:British Columbia; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000401:mortality; D002423:Cause of Death; D015331:Cohort Studies; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003693:Delirium / Q000188:drug therapy / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D019964:Mood Disorders / Q000188:drug therapy / Q000401:mortality; D009422:Nervous System Diseases / Q000139:chemically induced / Q000401:mortality; D011336:Probability; D016016:Proportional Hazards Models; D011618:Psychotic Disorders / Q000188:drug therapy / Q000401:mortality; D012140:Respiratory Tract Diseases / Q000139:chemically induced / Q000401:mortality; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents